Breaking News Instant updates and real-time market news.

MOH

Molina Healthcare

$60.63

-2.79 (-4.40%)

, UNH

UnitedHealth

$192.05

-0.875 (-0.45%)

11:32
10/13/17
10/13
11:32
10/13/17
11:32

Insurers, hospital operators fall after White House plans to cut subsidies

Insurers and hospital operators are moving lower after the White House has announced its intention to end key payments to insurers under the Affordable Care Act program. WHAT'S NEW: President Trump announced plans to cut off subsidy payments to insurers selling Affordable Care Act Coverage, a decision which leaked out after he signed an executive order pushing for new regulations to support cheap, loosely regulated health plans, Politco reported. The subsidies, worth an estimated $7B this year, may be halted almost immediately as Congress has not set aside funds for the program. The move comes after several failed GOP efforts to repeal Obamacare. TRUMP TWEETS: Trump, in a series of tweets Friday morning, called on Democrats to reach out to him for help to "fix" the "broken" law. In one, President Donald Trump tweeted, "The Democrats ObamaCare is imploding. Massive subsidy payments to their pet insurance companies has stopped. Dems should call me to fix!" The tweet comes after Trump said he talked with Senate Minority Leader Chuck Schumer about possible negotiations. Schumer, along with House Minority Leader Nancy Pelosi, issued a joint statement on Thursday calling Trump's decision "sabotage." INSURER IMPACT: The move is expected to be damaging to the marketplace, but less so than previously expected as many insurers have priced next year's plan higher and others have left Obamacare market, set to begin open enrollment on November 1, due to the healthcare uncertainty. Some states' regulators have directed ACA insurers to add a surcharge in lieu of payments, the Washington Post reports, but insurers elsewhere may be left to offer consumers discounts without reimbursement. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG). Insurers including Cigna, Health Care Service, Molina Healthcare, Highmark Health and Independence Blue Cross previously said they would continue in regions where they have filed to offer coverage after Cigna had announced it would depart from Maryland's exchange and Molina said it would withdraw from exchanges in Utah and Wisconsin. NEGATIVE FOR CENTENE: Leerink analyst Ana Gupte said the shutting off of the cost sharing subsidies on Affordable Care Act exchanges is most negative for Centene. The company is "highly profitable" on the exchanges at 15% of earnings, Gupte told investors in a research note. Molina Healthcare and Anthem are exposed on the top line but are losing money, the analyst added. She noted that UnitedHealth, Humana, and Aetna have exited the exchanges while WellCare has not been on them. PRICE ACTION: In late morning trading, insurers are falling, with Aetna down 1.15%, Anthem dropping 3%, Centene down 5.3%, Cigna falling 1.25% and Molina down 4.65%. Also moving lower are a number of hospital operators, including Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC), and Universal Health (UHS).

MOH

Molina Healthcare

$60.63

-2.79 (-4.40%)

UNH

UnitedHealth

$192.05

-0.875 (-0.45%)

CNC

Centene

$88.95

-4.73 (-5.05%)

WCG

WellCare

$168.10

-0.21 (-0.12%)

CI

Cigna

$184.75

-2.21 (-1.18%)

ANTM

Anthem

$184.09

-5.65 (-2.98%)

HNT

Health Net

HUM

Humana

$239.11

-2.335 (-0.97%)

AET

Aetna

$152.75

-1.7369 (-1.12%)

THC

Tenet

$13.26

-0.6 (-4.33%)

UHS

Universal Health

$105.70

-0.22 (-0.21%)

LPNT

LifePoint

$54.70

0.2 (0.37%)

HCA

HCA Healthcare

$74.16

-0.06 (-0.08%)

CYH

Community Health

$5.74

-0.27 (-4.49%)

  • 17

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

MOH Molina Healthcare
$60.63

-2.79 (-4.40%)

10/12/17
MSCO
10/12/17
NO CHANGE
Target $68
MSCO
Overweight
Morgan Stanley says Molina CEO pick brings valuable experience
Joseph Zubretsky brings valuable MCO experience to his post as the new CEO of Molina Healthcare (MOH), said Morgan Stanley analyst Zack Sopcak, who added that he would be a buyer on weakness in the shares given that he expects earnings power to be unlocked over the next 12-18 months. During Zubretsky's tenure as CEO of Hanover Insurance (THG), the company's stock rose nearly 20%, while Aetna (AET) shares were up about 4% during his 6 years as CFO there, noted Sopcak, who keeps an Overweight rating on Molina.
10/13/17
LEER
10/13/17
NO CHANGE
LEER
Ending of ACA subsidies most negative for Centene, says Leerink
Leerink analyst Ana Gupte says the shutting off of the cost sharing subsidies on Affordable Care Act exchanges is most negative for Centene (CNC). The company is "highly profitable" on the exchanges at 15% of earnings, Gupte tells investors in a research note. Molina Healthcare (MOH) and Anthem (ANTM) are exposed on the top line but are losing money, the analyst adds. She notes that UnitedHealth (UNH), Humana (HUM) and Aetna (AET) have exited the exchanges while WellCare (WCG) has not been on them. Centene in premarket trading is down 6% to $88.00 while Molina is down 3% to $61.50.
09/21/17
MUFG
09/21/17
INITIATION
Target $70
MUFG
Neutral
Molina Healthcare initiated with a Neutral at MUFG
MUFG analyst Jason Twizell started Molina Healthcare with a Neutral rating and $70 price target.
10/02/17
BERN
10/02/17
NO CHANGE
BERN
Bernstein does not anticipate ACA fix/repeal before 2018 election
While noting the resignation of Health Secretary Tom Price, Bernstein analyst Lance Wilkes says he does not anticipate an Affordable Care act fix or ACA repeal before the 2018 election. The analyst expects tax reform will "suck the oxygen out of the room" until close to the election. A fix for 2019 is possible, but faces the headwind of the 2018 election campaign, he contends, adding that he believes CSR funding could be included in a trade for the upcoming budget and the Health Insurance Fee could be suspended as part of tax reform, but both are not highly likely at this point. Publicly traded companies in the space include Aetna (AET), Anthem (ANTM), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
UNH UnitedHealth
$192.05

-0.875 (-0.45%)

08/30/17
ADAM
08/30/17
DOWNGRADE
Target $54
ADAM
Hold
The Advisory Board downgraded to Hold from Buy at Canaccord
Canaccord analyst Richard Close downgraded The Advisory Board (ABCO) to Hold from Buy based on the announced transaction to split the company by selling the Healthcare business to UnitedHealth's (UNH) Optum unit and the Education Business to Vista Equity Partners. Close lowered his price target to $54.29 on Advisory Board shares.
10/06/17
LEER
10/06/17
NO CHANGE
LEER
Leerink convinced Amazon entering drug distribution within two years
After calls with pharmacy benefit managers and retail pharmacy specialists, Leerink analyst Ana Gupte says she's convinced that Amazon.com (AMZN) "will almost certainly" enter the drug distribution value chain within two years, evolving into a more disruptive offering over time. Amazon's move is most threatening for retail pharmacies Walgreens Boots Alliance (WAB), CVS Health (CVS) and Wal-Mart (WMT), Gupte tells investors in a research note. The analyst calls Amazon both an opportunity and threat for Express Scripts (ESRX) and views UnitedHealth (UNH) and Humana (HUM) as "largely buffered." Gupte's conversations with specialists indicate Amazon is hiring relevant talent and is in active discussions with mid-market pharmacy benefit managers and possibly even with large players such as Prime Therapeutics. It is believed Amazon will start by capturing share in both the cash paying and third party mail order and possibly specialty pharmacy segments, Gupte notes. She expects Anthem (ANTM), Aetna (AET) and Cigna (CI) will likely to contemplate Amazon's entry in their upcoming PBM contract decisions.
CNC Centene
$88.95

-4.73 (-5.05%)

09/29/17
OPCO
09/29/17
NO CHANGE
Target $105
OPCO
Outperform
Centene price target raised to $105 from $95 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Centene to $105 and would continue to be a buyer of the stock. After attending meetings with management, the analyst believes the company "remains attractively positioned," especially in light of the failed efforts to repeal the Affordable Care Act. He sees reduced risk around repeal and keeps an Outperform rating on Centene.
10/13/17
MSCO
10/13/17
NO CHANGE
MSCO
Centene weakness a buying opportunity, says Morgan Stanley
WCG WellCare
$168.10

-0.21 (-0.12%)

10/09/17
COWN
10/09/17
INITIATION
Target $200
COWN
Outperform
WellCare initiated with an Outperform at Cowen
Cowen analyst Christine Arnold started WellCare Health Plans with an Outperform rating and $200 price target. The turnaround of the company's Medicare business has been "remarkably quick and successful," Arnold tells investors in a research note. The analyst believes organic enrollment growth and capital deployment will drive earnings growth.
09/21/17
MUFG
09/21/17
INITIATION
Target $204
MUFG
Overweight
WellCare initiated with an Overweight at MUFG
MUFG analyst Jason Twizell started WellCare Health Plans with an Overweight rating and $204 price target.
CI Cigna
$184.75

-2.21 (-1.18%)

07/12/17
FBCO
07/12/17
INITIATION
Target $195
FBCO
Neutral
Anthem initiated with a Neutral at Credit Suisse
Credit Suisse analyst Scott Fidel started Anthem with a Neutral rating and $195 price target. The company has produced slower earnings growth over the past decade relative to Managed Care peers and its returns on capital are also "sub-par relative to comps," the analyst contends. He believes Anthem is "entering a new chapter" following the failed Cigna (CI) acquisition and "uncertain future" of the Affordable Care Act's exchanges and Medicaid expansion.
10/09/17
JPMS
10/09/17
DOWNGRADE
Target $253
JPMS
Neutral
Humana downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Gary Taylor downgraded Humana (HUM) to Neutral saying insider sales and the August board appointment render it unlikely that acquisition discussions are yet occurring. Further, the Republican's failed attempts to repeal and replace the Affordable Care Act have diminished the probability of the health industry fee repeal, which would have boosted Humana's earnings power by 20%, Taylor tells investors in a research note. The analyst still believes, however, a bid for Humana by Cigna (CI) is plausible in 2018. He keeps a $253 price target on the shares. Humana closed Friday up $1.59 to $246.90.
ANTM Anthem
$184.09

-5.65 (-2.98%)

09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Express Scripts initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Express Scripts (ESRX) with a $68 price target and a Sector Perform rating. The analyst says that the company "faces an uncertain future" in the wake of the loss of its deal with Anthem ( ANTM), as he believes that it will have difficulty generating operating profit growth without Anthem.
HNT Health Net

06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
HUM Humana
$239.11

-2.335 (-0.97%)

10/09/17
10/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Humana (HUM) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor saying insider sales and the August board appointment render it unlikely that acquisition discussions are yet occurring. 2. Viacom (VIAB) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying as media and cable companies jockey "for self-preservation," Charter Communications (CHTR) will likely drop, or significantly curtail, distribution of Viacom's content. 3. PTC Therapeutics (PTCT) downgraded to Underweight from Neutral at JPMorgan with analyst Anupam Rama saying the company's valuation remains at near pre-FDA Advisory Committee meetings levels, despite multiple "mixed / inconclusive / negative" updates recently. 4. Medtronic (MDT) downgraded to Market Perform from Outperform at Wells Fargo with analyst Larry Biegelsen saying a "lull" in major product cycles will drive below average organic sales growth over at least the next few quarters. 5. Symantec (SYMC) was downgraded to Underperform from Market Perform at Cowen and to Hold from Buy at Standpoint Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AET Aetna
$152.75

-1.7369 (-1.12%)

THC Tenet
$13.26

-0.6 (-4.33%)

09/14/17
KEYB
09/14/17
NO CHANGE
KEYB
Tenet unlikely to find buyer for whole company, says KeyBanc
KeyBanc analyst Jason Gurda notes that Bloomberg is reporting that Tenet has hired advisers to explore strategic alternatives, including a potential sale. The analyst believes it is unlikely it will find a buyer for the whole company due to its high level of debt and the likely lack of interest from potential strategic buyers. However, Gurda does believe that Tenet could expand its effort to divest individual hospitals and/or its Conifer subsidiary at multiples that would be accretive to where the shares are currently trading and would accelerate de-leveraging. But it is not clear at the moment how far management is willing to go in breaking up the business, he adds.
09/14/17
RBCM
09/14/17
NO CHANGE
RBCM
Tenet unlikely to be acquired, says RBC Capital
After The Wall Street Journal reported that Tenet (THC) hired advisors to purse strategic options, RBC Capital analyst Frank Morgan says that all of Tenet probably won't be acquired, given its "significant" debt levels. He says that the company's ambulatory unit is the most likely part of the company to be sold or spun off. The analyst says that HCA (HCA) could be "interested" in some of Tenet's markets, but he does not believe that it wants to buy all of Tenet's hospitals. The analyst does not expect any deals made by Tenet to cause its share price to increase unless it manages to sell its hospitals for rates above their current market value. Morgan keeps a Sector Perform rating on the stock.
09/14/17
DBAB
09/14/17
NO CHANGE
Target $24
DBAB
Buy
Deutsche sees wide range of potential takeout values for Tenet
Deutsche Bank analyst Chris Rigg believes Tenet Healthcare's (THC) leverage makes for an "extremely wide" range of potential buyout prices. After the Wall Street Journal reported that the company is exploring strategic options including a possible sale, Rigg pegs $21-$41 per share as the potential buyout range. Also difficult is determining who would actually be interested and capable of buying Tenet, Rigg tells investors in a research note. HCA Holdings (HCA) has the financial wherewithal to do a deal, but the companies have significant overlap which could bring antitrust issues, the analyst contends. He sees private equity or an existing private equity-backed hospital chain as making more sense. Rigg has a Buy rating on Tenet with a $24 price target.
09/14/17
RHCO
09/14/17
NO CHANGE
RHCO
'Potential public suitors' for Tenet 'limited,' says SunTrust
SunTrust analyst David MacDonald says that "potential public suitors" for Tenet are "limited," while its free cash flow "remains sluggish." However, the analyst says that the company's assets are "intriguing," as its non-hospital assets are being undervalued by the market. He keeps a $16 price target and a Hold rating on the shares.
UHS Universal Health
$105.70

-0.22 (-0.21%)

06/06/17
MSCO
06/06/17
INITIATION
Target $124
MSCO
Equal Weight
Universal Health initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Universal Health with an Equal Weight rating and $124 price target, citing volume and price pressures on the hospital industry expected over the next several years.
05/31/17
PIPR
05/31/17
NO CHANGE
PIPR
Piper raises 'early caution flag' for Q2 hospital earnings
Following her firm's May outpatient survey, Piper Jaffray analyst Sarah James is putting up an "early caution flag" for Q2 hospital earnings. The May outpatient survey indicates April was the peak, declining in May, with indications that June could be below April as well, James tells investors in a research note. After four months of increases, the outpatient survey declined 50 basis points from the April peak to 2.5% year-over-year same-hospital admissions in May, the analyst adds. She views the decline as concerning amid "tenuous" investor sentiment and "optimistic" Q2 expectations. Hospitals that Piper covers include Community Health (CYH), HCA Holdings (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS).
08/16/17
PIPR
08/16/17
NO CHANGE
PIPR
Piper 'incrementally more bearish' on Hospital sector
Valuations in the Hospital sector have come in, but not enough, Piper Jaffray analyst Sarah James tells investors in a research note. She believes that contradictory to what the hospitals are suggesting, structural headwinds will continue for five-plus years. The analyst believes the group should be trading at a discount. James has an Underweight rating on Community Health Systems (CYH), Overweight ratings on HCA Holdings (HCA) and Universal Health (UHS), and Neutral ratings on LifePoint (LPNT) and Tenet (THC).
10/11/17
SPHN
10/11/17
INITIATION
Target $120
SPHN
Equal Weight
Universal Health initiated with an Equal Weight at Stephens
Stephens analyst Dana Hambly started Universal Health with an Equal Weight rating and $120 price target, noting that the company is the leader in the behavioral health industry, but that behavioral health volume growth has been below expectations and acute-care volume growth has slowed. Hambly said he would become more constructive on the stock should behavioral organic growth pick up.
LPNT LifePoint
$54.70

0.2 (0.37%)

09/06/17
CANT
09/06/17
NO CHANGE
CANT
Overweight
Irma threat a risk for HCA, public hospital peers, says Cantor
Cantor Fitzgerald analyst Joseph France noted that HCA Holdings (HCA), Community Health (CYH), LifePoint (LPNT), Tenet (THC) and Envision Healthcare (EVHC) all have business in Florida and Texas and are all down today on the potential threat from Hurricane Irma and the impact from Hurricane Harvey last week. HCA reports nearly half of its beds are in Florida and Texas while Envision has said in the past that more than half of its anesthesia business and about half of its legacy ER business is in those two states, noted France, who adds that Community Health, LifePoint and Tenet are less exposed to those states. The analyst keeps an Overweight rating on HCA shares.
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/07/17
LEER
06/07/17
UPGRADE
LEER
Outperform
Leerink upgrades hospitals HCA, LifePoint, Tenet to Outperform
Leerink analyst Ana Gupte last night upgraded hospitals HCA Holdings (HCA), LifePoint (LPNT) and Tenet healthcare (THC) to Outperform from Market Perform. She raised her price target for HCA to $100 from $90, for LifePoint to $74 from $73 and maintains a $27 price target for HCA. The targets offer upside of 21%, 20% and 62% respectively. Anthem's (ANTM) announced exit yesterday from the key swing state of Ohio's healthcare exchange could bring further attention to the need for stabilization funding through legislation, Gupte tells investors in a research note. She believes improving policy under the Trump Administration could drive upside to 2018 and 2019 consensus estimates. Further, the analyst thinks medium term downside risk from Republican's repeal and replace healthcare bill is likely better than feared as publicly traded hospitals are "heavily weighted to non-expansion states," which lessons the impact of Medicaid expansion funding cuts.
HCA HCA Healthcare
$74.16

-0.06 (-0.08%)

10/13/17
JEFF
10/13/17
NO CHANGE
Target $92
JEFF
Buy
HCA Healthcare price target lowered to $92 from $100 at Jefferies
Jefferies analyst Brian Tanquilut lowered his price target for HCA Healthcare to $92 after revising his estimates to account for several moving parts, including a retroactive reduction in Texas Medicaid Waiver funding and an "uncertain outlook" for healthcare utilization. His analysis, however, suggests HCA's 2018 EBITDA guidance should bracket consensus. Tanquilut calls hurricanes a Q3 "wildcard," believing weather reduced EBITDA in the quarter by greater than $100M. The analyst keeps a Buy rating on HCA shares.
CYH Community Health
$5.74

-0.27 (-4.49%)

08/18/17
DBAB
08/18/17
NO CHANGE
Target $8
DBAB
Hold
Community Health covenant breach a low likelihood, says Deutsche Bank
After analyzing his financial estimates and the company's financial position, Deutsche Bank analyst Chris Rigg believes the likelihood of Community Health Systems breaching its secured debt leverage covenant is low through 2019. The analyst says his analysis follows "market speculation over a near term credit event" at the company. He reduced his 2018 EBITDA estimate by 4% to $1.764B, which he notes is now well below consensus of $1.837B. Rigg keeps a Hold rating on Community Health with an $8 price target.
08/28/17
JEFF
08/28/17
NO CHANGE
JEFF
Buy
HCA has 11% of its beds in Harvey impacted areas, says Jefferies
Jefferies analyst Brian Tanquilut points out that HCA Holdings (HCA) has 11% of its beds in areas impacted by severe weather from Hurricane Harvey. The analyst expects the hurricane to cause a "notable disruption," specifically for hospitals, physician offices, surgery centers, and labs. Investors are likely to take a long-term view of Hurricane Harvey, however, as it is a one-time issue and thus excluded from operating and financial results, Tanquilut tells investors in a research note. He sees both Tenet (THC) and Community Health (CYH) being minimally impacted from the storm. Envision Healthcare's (EVHC) AmSurg segment has three ambulatory surgery centers in the impacted markets, while Surgery Partners (SGRY) has only one facility in Houston, the analyst adds.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.